Skip to content Skip to footer
Subscribe Now

NEWS

Genentech & Orionis
Genentech Collaborates with Orionis to Identify and Develop Molecular Glue Therapies for Cancer Targets
Shots: Genentech has entered into a multi-year collaboration with Orionis to discover small-molecule monovalent glue drugs for novel & difficult oncology targets using Orionis’ Allo-Glue platform As per the deal, Orionis will receive $105M upfront & ~$2B in research, development, commercial, & sales milestones, with tiered royalties; Orionis will lead discovery & optimization, while Genentech…
May 22, 2025
Celltrion
Celltrion’s Yuflyma (Biosimilar, Humira) Receives the US FDA’s Interchangeability Designation for All Presentations
Shots: FDA has granted interchangeability designation to Yuflyma, a biosimilar version of Humira (adalimumab) for prefilled syringe (40mg) & autoinjectors (40 & 80mg) expanding on the prior designation for the 20mg & 80mg prefilled syringes Designation was based on P-III interchangeability trial showing comparable PK, efficacy, safety, & immunogenicity in pts with mod. to sev.…
May 22, 2025
Ramsoft & Therapixel
RamSoft and Therapixel Form a Commercial Partnership For an Integrated AI Breast Imaging Solution
Shots: RamSoft Inc. and Therapixel have entered into a commercial partnership to integrate Therapixel’s MammoScreen AI-powered breast imaging software into RamSoft’s PowerServer and OmegaAI platforms This collaboration integrates Therapixel's MammoScreen, breast imaging AI, directly into RamSoft's platforms Recent studies showed that MammoScreen improves radiologist performance with 8% higher sensitivity, 2% higher specificity, and 24% faster…
May 21, 2025
Innocare Pharma
China’s NMPA Grants Approval to InnoCare Pharma’s Minjuvi + Lenalidomide to Treat R/R DLBCL
Shots: InnoCare Pharma has approved Minjuvi (tafasitamab) + Lenalidomide, followed by Minjuvi monotx., for treating adult pts. with r/r diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT) Tafasitamab, a humanized Fc-modified cytolytic CD19-targeting immunotherapy, combined with lenalidomide, is already approved for treating eligible DLBCL pts. in Hong Kong, Macau,…
May 21, 2025
Kalivir Immunotherapeutics
KaliVir Immunotherapeutics Reports Completion of First Cohort of P-I/Ib (STEALTH-001) Study in Advanced Solid Tumors
Shots: KaliVir Immunotherapeuticsreported completion of the first cohort in P-I/Ib (STEALTH-001) study evaluating VET3-TGI as a monotx. and in combination with a checkpoint inhibitor in advanced, unresectable, or metastatic solid tumor pts.  The Data Safety Committee reviewed initial safety data and approved the progression of VET3-TGI to the next IT and IV dosing cohorts VET3-TGI is an…
May 21, 2025
Fresenius Kabi
Fresenius Kabi Launches Tyenne (Biosimilar, Actemra) Across Canada 
Shots:  Following the launch of Idacio (adalimumab) Citrate-free, Fresenius Kabi Canada has launched Tyenne (IV/SC), a biosimilar version of Actemra (tocilizumab) from Roche, now available in Canada  Tyenne (IL-6 receptor blocker) is approved to treat inflammatory and immune conditions such as rheumatoid arthritis (RA), giant cell arteritis (GCA), Polyarticular juvenile idiopathic arthritis (pJIA), and systemic…
May 21, 2025
Vant AI & Blueprint Medicines
VantAI and Blueprint Medicines Expands License Agreement to Advance Induced Proximity Drug Discovery
Shots: VantAI and Blueprint Medicines have expanded their 2022 collaboration, adding new drug target programs to develop therapies for critical medical needs As per the expansion, VantAI will receive up to $1.67B in total including ~$270M R&D and regulatory milestones, and $1.4B commercial milestones across four joint target programs, along with tiered mid-single-digit sales based…
May 21, 2025
Load more